kynurenine has been researched along with Renal Insufficiency, Chronic in 17 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In symptomatic patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, circulating levels of long-chain acylcarnitines were independently associated with measures of maladaptive LV remodeling, and metabolic perturbations lessened after procedure completion." | 7.88 | Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. ( Elmariah, S; Farrell, LA; Furman, D; Gerszten, RE; Lindman, BR; Morningstar, JE; Rhee, EP; Shi, X, 2018) |
| "Amelioration of both oxidative and inflammation status after cholesterol lowering treatment in CKD might be mediated by restoration of antioxidant taurine concentrations during therapy (from 51." | 5.20 | Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. ( Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A, 2015) |
| "In symptomatic patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, circulating levels of long-chain acylcarnitines were independently associated with measures of maladaptive LV remodeling, and metabolic perturbations lessened after procedure completion." | 3.88 | Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. ( Elmariah, S; Farrell, LA; Furman, D; Gerszten, RE; Lindman, BR; Morningstar, JE; Rhee, EP; Shi, X, 2018) |
| " Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)." | 3.83 | Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016) |
| "CC-chemokines and kynurenine pathway (KP) metabolites are associated with accelerated atherosclerosis in chronic kidney disease (CKD) patients." | 3.76 | 3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease. ( Kowalewska, A; Mysliwiec, M; Pawlak, D; Pawlak, K, 2010) |
| "Serum samples of 32 patients with ESRD (n = 13) and CKD (n = 19) were analyzed using chemical isotope labeling liquid chromatography-mass spectrometry metabolomics approach." | 1.91 | Metabolomics profiling distinctively identified end-stage renal disease patients from chronic kidney disease patients. ( Abdel Rahman, A; Alabdaljabar, MS; Dahabiyeh, LA; Hussein, MH; Jacob, M; Nimer, RM; Sabi, EM; Sumaily, KM, 2023) |
| "Kynurenine levels were significantly lower in the group under RASis compared to the untreated group (1." | 1.56 | RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus. ( Benvenga, S; Bolignano, D; Buemi, M; Cernaro, V; Cigala, RM; Crea, F; De Stefano, C; Ferlazzo, VT; Gembillo, G; Genovese, ARR; Loddo, S; Macaione, V; Santoro, D; Vita, R, 2020) |
| "LP533401 is an inhibitor of peripheral serotonin synthesis." | 1.56 | Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. ( Cylwik, B; Domaniewski, T; Kalaska, B; Mor, A; Pawlak, D; Pawlak, K; Sieklucka, B; Zieminska, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 8 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, JA | 2 |
| Richards, S | 2 |
| Whelan, SA | 2 |
| Yoo, SB | 1 |
| Russell, TL | 1 |
| Arinze, N | 1 |
| Lotfollahzadeh, S | 2 |
| Napoleon, MA | 2 |
| Belghasem, M | 2 |
| Lee, N | 2 |
| Dember, LM | 2 |
| Ravid, K | 2 |
| Chitalia, VC | 3 |
| Arinze, NV | 1 |
| Yin, W | 1 |
| Ravid, JD | 1 |
| Hassan Kamel, M | 1 |
| Siracuse, JJ | 1 |
| Anderson, S | 1 |
| Farber, A | 1 |
| Sherr, D | 1 |
| Francis, J | 1 |
| Hamburg, NM | 1 |
| Rahimi, N | 1 |
| Wee, HN | 1 |
| Liu, JJ | 1 |
| Ching, J | 1 |
| Kovalik, JP | 1 |
| Lim, SC | 1 |
| Dahabiyeh, LA | 1 |
| Nimer, RM | 1 |
| Sumaily, KM | 1 |
| Alabdaljabar, MS | 1 |
| Jacob, M | 1 |
| Sabi, EM | 1 |
| Hussein, MH | 1 |
| Abdel Rahman, A | 1 |
| Hui, Y | 1 |
| Zhao, J | 3 |
| Yu, Z | 1 |
| Wang, Y | 1 |
| Qin, Y | 1 |
| Zhang, Y | 1 |
| Xing, Y | 1 |
| Han, M | 1 |
| Wang, A | 1 |
| Guo, S | 1 |
| Yuan, J | 1 |
| Zhao, Y | 1 |
| Ning, X | 1 |
| Sun, S | 1 |
| Cernaro, V | 1 |
| Loddo, S | 1 |
| Macaione, V | 1 |
| Ferlazzo, VT | 1 |
| Cigala, RM | 1 |
| Crea, F | 1 |
| De Stefano, C | 1 |
| Genovese, ARR | 1 |
| Gembillo, G | 1 |
| Bolignano, D | 1 |
| Santoro, D | 1 |
| Vita, R | 1 |
| Buemi, M | 1 |
| Benvenga, S | 1 |
| Cheng, Y | 1 |
| Li, Y | 1 |
| Benkowitz, P | 1 |
| Lamina, C | 1 |
| Köttgen, A | 1 |
| Sekula, P | 1 |
| Mor, A | 1 |
| Pawlak, K | 2 |
| Kalaska, B | 1 |
| Domaniewski, T | 1 |
| Sieklucka, B | 1 |
| Zieminska, M | 1 |
| Cylwik, B | 1 |
| Pawlak, D | 2 |
| Elmariah, S | 1 |
| Farrell, LA | 1 |
| Furman, D | 1 |
| Lindman, BR | 1 |
| Shi, X | 1 |
| Morningstar, JE | 1 |
| Rhee, EP | 1 |
| Gerszten, RE | 1 |
| Kolachalama, VB | 1 |
| Shashar, M | 1 |
| Alousi, F | 1 |
| Shivanna, S | 1 |
| Rijal, K | 1 |
| Belghasem, ME | 1 |
| Walker, J | 1 |
| Matsuura, S | 1 |
| Chang, GH | 1 |
| Gibson, CM | 1 |
| Francis, JM | 1 |
| Bao, YS | 1 |
| Ji, Y | 1 |
| Zhao, SL | 1 |
| Ma, LL | 1 |
| Xie, RJ | 1 |
| Na, SP | 1 |
| Zinellu, A | 2 |
| Sotgia, S | 2 |
| Mangoni, AA | 2 |
| Sanna, M | 1 |
| Satta, AE | 2 |
| Carru, C | 2 |
| Sotgiu, E | 1 |
| Ena, S | 1 |
| Schefold, JC | 1 |
| Zeden, JP | 1 |
| Fotopoulou, C | 1 |
| von Haehling, S | 1 |
| Pschowski, R | 1 |
| Hasper, D | 1 |
| Volk, HD | 1 |
| Schuett, C | 1 |
| Reinke, P | 1 |
| Kowalewska, A | 1 |
| Mysliwiec, M | 1 |
2 reviews available for kynurenine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.
Topics: Acute Kidney Injury; Animals; Humans; Kynurenine; Renal Insufficiency, Chronic | 2021 |
The Role of Tryptophan Metabolism in the Occurrence and Progression of Acute and Chronic Kidney Diseases.
Topics: Acute Kidney Injury; Humans; Kynurenine; Renal Insufficiency, Chronic; Signal Transduction; Tryptoph | 2023 |
2 trials available for kynurenine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of renal function.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Hypertension; Kidney Function Tes | 2013 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Res | 2015 |
13 other studies available for kynurenine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD.
Topics: Animals; Aorta; Carotid Artery Injuries; Carotid Artery Thrombosis; Culture Media; Enzyme Induction; | 2021 |
Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Line; Disease M | 2022 |
Metabolomics profiling distinctively identified end-stage renal disease patients from chronic kidney disease patients.
Topics: Biomarkers; Disease Progression; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Kynure | 2023 |
RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Angiotensins; Correlation of Data; Cross-Sectional Studies; Diabetes Mellit | 2020 |
The relationship between blood metabolites of the tryptophan pathway and kidney function: a bidirectional Mendelian randomization analysis.
Topics: Biomarkers; Disease Progression; Glomerular Filtration Rate; Humans; Indican; Indoles; Kynurenine; M | 2020 |
Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401.
Topics: Animals; Bone Diseases, Metabolic; Calcification, Physiologic; Kynurenine; Male; Mice; Osteoblasts; | 2020 |
Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Biomarkers; Carnitine; Choline; Diabetes Complications; Fe | 2018 |
Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Indican; Kynurenine; Male; Metabolomics; Midd | 2018 |
Serum levels and activity of indoleamine2,3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease.
Topics: Adult; Biomarkers; Case-Control Studies; Female; Glomerular Filtration Rate; Humans; Indoleamine-Pyr | 2013 |
Simultaneous determination of plasma creatinine, uric acid, kynurenine and tryptophan by high-performance liquid chromatography: method validation and in application to the assessment of renal function.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Hypertension; Kidney | 2015 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema | 2016 |
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Topics: 5-Hydroxytryptophan; Adult; Aged; C-Reactive Protein; Case-Control Studies; Creatinine; Female; Huma | 2009 |
3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Atherosclerosis; Chemokine CCL2; Chemokine CCL4; Chemokines, | 2010 |